Related Experiment Videos
P53 expression is a factor for prognostic assessment in breast sarcoma.
Maria do Socorro Maciel1, Leda C Viegas, Suely Nonogaki
1Hospital do Câncer AC Camargo, São Paulo, Brasil.
Breast Cancer Research and Treatment
|May 11, 2002
Summary
p53 protein expression is a significant prognostic marker in breast sarcoma. Positive p53 expression correlates with poorer survival rates and increased risk of recurrence and metastasis in these rare tumors.
Area of Science:
- Oncology
- Pathology
- Surgical Oncology
Background:
- Breast sarcomas are rare malignant tumors distinct from carcinomas.
- Prognostic markers are crucial for guiding treatment and predicting outcomes in breast sarcoma patients.
Purpose of the Study:
- To evaluate clinical and anatomopathological findings in breast sarcoma.
- To investigate the expression of the protein p53 as a prognostic marker in breast sarcoma.
Main Methods:
- Immunohistochemical analysis of p53 protein expression in 30 breast sarcoma tissue samples.
- Correlation of p53 expression with patient survival, local recurrence, and metastatic disease.
- Comparison of p53 expression with clinicopathological features such as age, menopausal status, tumor size, stage, and histological type.
Main Results:
- p53 immunopositivity was observed in 50% of breast sarcoma cases.
- Patients with positive p53 expression had significantly lower 5-year survival rates (55.1%) compared to p53-negative patients (92.3%).
- Positive p53 expression was associated with local recurrence (75%) and metastatic disease (77%), and a worse prognosis in specific subgroups (older patients, larger tumors, high grade, malignant fibrous histiocytoma).
Conclusions:
- p53 protein expression is a valuable prognostic marker for breast sarcoma.
- Positive p53 expression indicates a poorer prognosis and higher risk of disease progression.
- Further research into p53's role may improve risk stratification and therapeutic strategies for breast sarcoma.